New pill shows promise against fatty liver disease in Mid-Stage trial
NCT ID NCT06168383
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an experimental drug called HSK31679 in 186 Chinese adults with non-alcoholic steatohepatitis (NASH), a serious liver condition. Participants took either 80 mg, 160 mg, or a placebo daily for 52 weeks. The goal was to see if the drug could improve liver damage and reduce scarring without making the disease worse.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC STEATOHEPATITIS (NASH) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Tsinghua Changgung Hospital, Tsinghua University
Beijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New ultrasound device could replace costly MRI for liver disease detection
- Diabetes drugs may reverse fatty liver damage in new trial
- Blood tests could spot hidden liver risk in diabetics
- One Breath-Hold MRI could replace liver biopsies for NASH
- New shot shows promise against fatty liver disease
- Ice cream as medicine? study tests sweet treat for fatty liver and diabetes